TO THE Import Manager Pharmaceutical Import Profile — United Arab Emirates (DGFT 2022–2026)

Name: TO THE Import Manager Pharmaceutical Import Records from India — 3 Products, $71.4K FOB USD (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

TO THE Import Manager — Pharmaceutical Importer Profile (2026) | 3 Products, $71.4K Trade | TransData Nexus

TO THE Import Manager

Pharmaceutical Importer · United Arab Emirates · Advanced Oncology Focus · $71.4K Total Trade · DGFT Verified

TO THE Import Manager is a pharmaceutical importer based in United Arab Emirates with a total trade value of $71.4K across 3 products in 1 therapeutic categories. Based on 18 verified import shipments from Indian Customs (DGFT) records, the company actively imports across multiple product segments. TO THE Import Manager sources from 8 verified Indian suppliers, with Omnilife Healthcare accounting for 48.4% of imports.

TO THE Import Manager — Import Portfolio & Supplier Network

TO THE Import Manager import network — 3 products from Indian suppliers. Source: Indian Customs (DGFT).

Who Are the Verified Indian Suppliers to TO THE Import Manager?

Customs-verified supplier relationships from Indian DGFT records

Supplier	Value	Shipments	Share
Omnilife Healthcare	$3.9M	154	48.4%
Kings Global Biotech Limited	$3.3M	956	41.6%
9m India Limited	$641.9K	40	8.0%

What Formulations Does TO THE Import Manager Import?

Formulation	Value	Ships
Pharmaceutical products for human	$700.1K	22
Pharmaceutical products for human use-	$332.2K	11
Pharmaceutical product for human	$237.7K	5
Pharmaceutical products for human use	$218.3K	40
Pharmaceutical product for human	$209.3K	5
Pharmaceutical product for human use-	$200.0K	4
Pharmaceutical product for human	$200.0K	4
Pharmaceutical product for human use-	$189.2K	7
Pharmaceutical products for human use-	$185.5K	6
Pharmaceutical product for human use-	$181.6K	4
Pharmaceutical products for human use-	$134.9K	16
Pharmaceutical products for human use-	$132.5K	22
Pharmaceutical product for human use	$126.6K	4
Pharmaceutical products for human	$124.6K	57
Pharmaceutical product for human use -	$100.8K	4

TO THE Import Manager imports 604 distinct pharmaceutical formulations. Showing top 15 by value. For full formulation-level data, contact TransData Nexus.

Import Portfolio — Top 3 by Import Value

#	Product	Category	Value	Ships	Share	Rk
1	Lenvatinib	Advanced Oncology	$44.1K	11	2.1%	6
2	Olaparib	Advanced Oncology	$21.6K	4	2.3%	5
3	Lomustine	Advanced Oncology	$5.7K	3	5.5%	2

TO THE Import Manager imports 3 pharmaceutical products across 1 categories into United Arab Emirates totaling $71.4K.

TO THE Import Manager — Corporate Profile & Information

Company type, headquarters, distribution network, and industry role

1Company Overview

TO THE Import Manager is a pharmaceutical importer and buyer based in the United Arab Emirates (UAE). Operating as a medical warehouse, the company specializes in importing finished pharmaceutical formulations, including tablets, capsules, syrups, and injections, from India. With a total import value of $71,000 USD across 18 shipments, TO THE Import Manager focuses exclusively on the Advanced Oncology therapeutic category, importing three distinct products. The company's portfolio is highly concentrated, with the top three products—Lenvatinib, Olaparib, and Lomustine—accounting for 100% of its imports. This indicates a strategic emphasis on oncology treatments, aligning with the UAE's growing demand for specialized cancer therapies.

2Distribution Network

While specific details about TO THE Import Manager's warehouse locations and logistics capabilities are not publicly available, as a licensed medical warehouse in the UAE, the company is authorized to store, import, and distribute medical products within the country. The UAE's strategic location and advanced infrastructure facilitate efficient distribution, enabling TO THE Import Manager to serve both domestic and regional markets effectively. The company's distribution network likely leverages the UAE's well-developed logistics and transportation systems to ensure timely delivery of pharmaceutical products.

3Industry Role

In the UAE's pharmaceutical supply chain, TO THE Import Manager functions primarily as a medical warehouse. This role involves importing finished pharmaceutical formulations from international suppliers, particularly from India, and distributing them within the UAE. By focusing on the Advanced Oncology therapeutic category, the company addresses a critical segment of the market, supplying specialized cancer treatments to meet the needs of healthcare providers and patients in the region.

TransData Nexus Research · Company registries, industry databasesMar 2026

Supplier Relationship Intelligence — TO THE Import Manager

Sourcing concentration, supply chain resilience, and strategic implications

1Sourcing Concentration Analysis

TO THE Import Manager's sourcing strategy is highly concentrated, with the top three products—Lenvatinib, Olaparib, and Lomustine—comprising 100% of its imports. This indicates a deliberate focus on specific oncology treatments, potentially to establish strong partnerships with key suppliers and ensure consistent product availability. However, such concentration may pose risks, including supply chain disruptions if any of these suppliers face operational challenges. The company's reliance on a limited number of products suggests a strategic choice to specialize in high-demand oncology therapies, but it also underscores the importance of maintaining robust relationships with these suppliers to mitigate potential risks.

2Supply Chain Resilience

The resilience of TO THE Import Manager's supply chain is closely tied to its partnerships with Indian suppliers. The company imports finished pharmaceutical formulations from eight verified Indian suppliers, with the top three—OMNILIFE HEALTHCARE, KINGS GLOBAL BIOTECH LIMITED, and 9M INDIA LIMITED—accounting for the majority of imports. This diversified supplier base enhances supply chain stability, reducing dependency on a single source. However, the company's portfolio concentration on three products means that any disruptions in the supply of these specific items could significantly impact operations. Ensuring compliance with UAE regulations and maintaining quality standards are crucial for sustaining a resilient supply chain.

Importing Pharmaceuticals into United Arab Emirates — Regulatory Framework

Regulatory authority, GMP requirements, import licensing for United Arab Emirates

1Regulatory Authority & Framework

The Emirates Drug Establishment (EDE) is the primary regulatory authority overseeing medical products, the pharmacy profession, and pharmaceutical establishments in the UAE. Established under Federal Decree-Law No. 38 of 2024, the EDE is responsible for regulating the import, distribution, and marketing of medical products, including pharmaceuticals. The EDE's mandate includes ensuring the safety, efficacy, and quality of medical products available in the UAE market. The Federal Decree-Law No. 38 of 2024 aims to enhance supply chain security and streamline the development, approval, manufacturing, marketing, and distribution of medical products, solidifying the UAE's position as a globally trusted hub for the pharmaceutical and medical industries.

2Import Licensing & GMP

Importing pharmaceutical products into the UAE requires obtaining an import license and permit from the EDE. This process involves submitting detailed information about the products, including their quantities, types, and shipping methods. Additionally, the EDE mandates that imported pharmaceutical products comply with Good Manufacturing Practice (GMP) standards recognized by international bodies such as the World Health Organization (WHO) and the Pharmaceutical Inspection Co-operation Scheme (PIC/S). Importers must ensure that their suppliers adhere to these standards to maintain product quality and regulatory compliance. (uaelegislation.gov.ae)

TO THE Import Manager — Procurement Pattern Analysis

Product strategy, sourcing profile, and market positioning

1Product Strategy

TO THE Import Manager's focus on the Advanced Oncology therapeutic category reflects a strategic decision to specialize in high-demand cancer treatments. The UAE's increasing prevalence of chronic diseases, including cancer, drives the demand for specialized oncology therapies. By concentrating on this segment, TO THE Import Manager can leverage its expertise to meet the specific needs of healthcare providers and patients, positioning itself as a key player in the UAE's oncology market.

2Sourcing Profile

TO THE Import Manager's sourcing strategy involves importing finished pharmaceutical formulations from Indian suppliers, with a particular emphasis on oncology products. The company imports a total of 604 unique formulations, indicating a diverse product range within the oncology category. This approach allows TO THE Import Manager to offer a comprehensive portfolio of oncology treatments, catering to various patient needs and preferences.

3Market Positioning

By specializing in the Advanced Oncology therapeutic category, TO THE Import Manager serves a niche segment of the UAE pharmaceutical market. The company's focus on high-demand oncology products positions it to supply hospitals, specialized clinics, and government health institutions involved in cancer treatment. This strategic positioning enables TO THE Import Manager to build strong relationships with key stakeholders in the UAE's healthcare sector.

Seller's Guide — How to Become a Supplier to TO THE Import Manager

Opportunity assessment, qualifications, and practical approach strategy

1Opportunity Assessment

There is a realistic opportunity for new Indian suppliers to partner with TO THE Import Manager, given the company's focus on oncology products and its established distribution network in the UAE. Indian exporters can explore this opportunity by ensuring their products meet the UAE's regulatory standards and by establishing strong relationships with TO THE Import Manager. Additionally, identifying gaps in TO THE Import Manager's current sourcing, such as specific oncology treatments not currently imported, could present mutually beneficial opportunities.

2Requirements & Qualifications

Indian exporters seeking to supply TO THE Import Manager and the UAE market must ensure their products are registered with the EDE and comply with GMP standards recognized by international bodies such as WHO and PIC/S. Additionally, products must meet the UAE's labeling requirements, including Arabic and English labeling, and adhere to serialization mandates for tracking and monitoring. Ensuring compliance with these standards is essential for successful market entry. (uaelegislation.gov.ae)

3How to Approach

Frequently Asked Questions — TO THE Import Manager

What products does TO THE Import Manager import from India?

TO THE Import Manager imports 3 pharmaceutical products across 1 categories. Top imports: Lenvatinib ($44.1K), Olaparib ($21.6K), Lomustine ($5.7K).

Who supplies pharmaceuticals to TO THE Import Manager from India?

TO THE Import Manager sources from 8 verified Indian suppliers. The primary supplier is Omnilife Healthcare (48.4% of imports, $3.9M).

What is TO THE Import Manager's total pharmaceutical import value?

TO THE Import Manager's total pharmaceutical import value from India is $71.4K, based on 18 verified shipments in Indian Customs (DGFT) data.

What therapeutic categories does TO THE Import Manager focus on?

TO THE Import Manager imports across 1 categories. The largest: Advanced Oncology (100.0%).

Get Full TO THE Import Manager Import Intelligence

Access shipment-level details, supplier connections, pricing data, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify import regulations and drug registration requirements with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. For current shipment-level data, contact TransData Nexus.